(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid


CAS No. : 141505-32-0

(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid,141505-32-0
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:M103201
Synonyms:(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
Molecular Formula:C19H34N2O5
Molecular Weight:370.49
Target:cyclooxygenase inhibitor
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:Solid powder
Purity: > 98%
Cat No:M103201
Cas No:141505-32-0
Product-Name:(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid
IUPAC Name:(2S)-2,6-diaminohexanoic acid;(2S)-2-[4-(2-methylpropyl)phenyl]propanoic acid;hydrate
InChI:InChI=1S/C13H18O2.C6H14N2O2.H2O/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15;7-4-2-1-3-5(8)6(9)10;/h4-7,9-10H,8H2,1-3H3,(H,14,15);5H,1-4,7-8H2,(H,9,10);1H2/t10-;5-;/m00./s1
InChIKey:ZLGIZCLYTDPXEP-LQDNOSPQSA-N
SMILES:CC(C)CC1=CC=C(C=C1)C(C)C(=O)O.C(CCN)CC(C(=O)O)N.O
Dexibuprofen lysine is a nonsteroidal anti-inflammatory that acts as cyclooxygenase inhibitor.

1: Sánchez-López E, Egea MA, Cano A, Espina M, Calpena AC, Ettcheto M, Camins A, Souto EB, Silva AM, García ML. PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization. Colloids Surf B Biointerfaces. 2016 May 3;145:241-250. doi: 10.1016/j.colsurfb.2016.04.054. [Epub ahead of print] PubMed PMID: 27187188.
2: Akhlaq M, Arshad MS, Mudassir AM, Hussain A, Kucuk I, Haj-Ahmad R, Rasekh M, Ahmad Z. Formulation and evaluation of anti-rheumatic dexibuprofen transdermal patches: a quality-by-design approach. J Drug Target. 2016 Aug;24(7):603-12. doi: 10.3109/1061186X.2015.1116538. Epub 2015 Dec 17. PubMed PMID: 26586147.
3: Li Y, Zhou Y, Jiang J, Wang X, Fu Y, Gong T, Sun X, Zhang Z. Mechanism of brain targeting by dexibuprofen prodrugs modified with ethanolamine-related structures. J Cereb Blood Flow Metab. 2015 Dec;35(12):1985-94. doi: 10.1038/jcbfm.2015.160. Epub 2015 Jul 8. PubMed PMID: 26154870; PubMed Central PMCID: PMC4671119.
4: El-Houssieny BM, El-Dein EZ, El-Messiry HM. Enhancement of solubility of dexibuprofen applying mixed hydrotropic solubilization technique. Drug Discov Ther. 2014 Aug;8(4):178-84. PubMed PMID: 25262596.
5: Jin SG, Yousaf AM, Son MW, Jang SW, Kim DW, Kim JO, Yong CS, Kim JH, Choi HG. Mechanical properties, skin permeation and in vivo evaluations of dexibuprofen-loaded emulsion gel for topical delivery. Arch Pharm Res. 2015 Feb;38(2):216-22. doi: 10.1007/s12272-014-0367-8. Epub 2014 Mar 24. PubMed PMID: 24988989.
6: Zamani O, Böttcher E, Rieger JD, Mitterhuber J, Hawel R, Stallinger S, Eller N. Comparison of safety, efficacy and tolerability of dexibuprofen and ibuprofen in the treatment of osteoarthritis of the hip or knee. Wien Klin Wochenschr. 2014 Jun;126(11-12):368-75. doi: 10.1007/s00508-014-0544-2. Epub 2014 Apr 17. PubMed PMID: 24740137.
7: Derry S, Best J, Moore RA. Single dose oral dexibuprofen [S(+)-ibuprofen] for acute postoperative pain in adults. Cochrane Database Syst Rev. 2013 Oct 23;(10):CD007550. doi: 10.1002/14651858.CD007550.pub3. Review. PubMed PMID: 24151035.
8: Erratum: Safety and efficacy of an add-on therapy with curcumin phytosome and piperine and/or lipoic acid in subjects with a diagnosis of peripheral neuropathy treated with dexibuprofen [Erratum]. J Pain Res. 2013 Aug 26;6:641. eCollection 2013. PubMed PMID: 24009429; PubMed Central PMCID: PMC3762669.
9: Abdelbary G, Makhlouf A. Adoption of polymeric micelles to enhance the oral bioavailability of dexibuprofen: formulation, in-vitro evaluation and in-vivo pharmacokinetic study in healthy human volunteers. Pharm Dev Technol. 2014 Sep;19(6):717-27. doi: 10.3109/10837450.2013.823994. Epub 2013 Aug 13. PubMed PMID: 23937590.
10: Di Pierro F, Settembre R. Safety and efficacy of an add-on therapy with curcumin phytosome and piperine and/or lipoic acid in subjects with a diagnosis of peripheral neuropathy treated with dexibuprofen. J Pain Res. 2013 Jul 3;6:497-503. doi: 10.2147/JPR.S48432. Print 2013. Erratum in: J Pain Res. 2013;6:641. PubMed PMID: 23861596; PubMed Central PMCID: PMC3704545.
11: Kim CK, Callaway Z, Choung JT, Yu JH, Shim KS, Kwon EM, Koh YY. Dexibuprofen for fever in children with upper respiratory tract infection. Pediatr Int. 2013 Aug;55(4):443-9. doi: 10.1111/ped.12125. PubMed PMID: 23659181.
12: Muralidharan S. Pharmacokinetic-pharmacodynamic model of newly developed dexibuprofen sustained release formulations. ISRN Pharm. 2012;2012:451481. doi: 10.5402/2012/451481. Epub 2012 Dec 6. PubMed PMID: 23316393; PubMed Central PMCID: PMC3534360.
13: Awad H, Aboul-Enein HY, Lashin S. A validated enantioselective HPLC assay of dexibuprofen in dexibuprofen tablet formulations. Biomed Chromatogr. 2012 Apr;26(4):502-6. PubMed PMID: 22493788.
14: Zhang X, Liu X, Gong T, Sun X, Zhang ZR. In vitro and in vivo investigation of dexibuprofen derivatives for CNS delivery. Acta Pharmacol Sin. 2012 Feb;33(2):279-88. doi: 10.1038/aps.2011.144. PubMed PMID: 22301864; PubMed Central PMCID: PMC4010340.
15: Noh YH, Lim HS, Cho SH, Ghim JL, Choe S, Jung JA, Kim UJ, Park KM, Jang MJ, Bae KS. Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. Clin Ther. 2011 Sep;33(9):1132-41. doi: 10.1016/j.clinthera.2011.07.019. Epub 2011 Aug 24. PubMed PMID: 21864907.
16: Xu MJ, Zou C, H Chu J, Wu T, Liu SJ, Zhang J, Chen M, Liu F, Xiong NN, Ju WZ, S Tan H. Pharmacokinetics and bioequivalence of single dose and multiple doses of immediate- and extended-release formulations of dexibuprofen in healthy Chinese subjects. Int J Clin Pharmacol Ther. 2011 Mar;49(3):237-46. PubMed PMID: 21329626.
17: Rasheed A, Kumar CK, Mishra A. Synthesis, hydrolysis studies and phamacodynamic profiles of amide prodrugs of dexibuprofen with amino acids. J Enzyme Inhib Med Chem. 2011 Oct;26(5):688-95. doi: 10.3109/14756366.2010.548327. Epub 2011 Jan 21. PubMed PMID: 21250819.
18: Muralidharan S, Meyyanathan SN. Development and Validation of a HPLC and an UV Spectrophotometric Methods for Determination of Dexibuprofen in Pharmaceutical Preparations. ISRN Pharm. 2011;2011:948314. doi: 10.5402/2011/948314. Epub 2011 Jul 5. PubMed PMID: 22389866; PubMed Central PMCID: PMC3263711.
19: Kim SR, Kim JK, Park JS, Kim CK. Dry elixir formulations of dexibuprofen for controlled release and enhanced oral bioavailability. Int J Pharm. 2011 Feb 14;404(1-2):301-7. doi: 10.1016/j.ijpharm.2010.11.020. Epub 2010 Nov 18. PubMed PMID: 21093566.
20: De la Cruz JP, Reyes JJ, Ruiz-Moreno MI, Lopez-Villodres JA, Jebrouni N, Gonzalez-Correa JA. Differences in the in vitro antiplatelet effect of dexibuprofen, ibuprofen, and flurbiprofen in human blood. Anesth Analg. 2010 Dec;111(6):1341-6. doi: 10.1213/ANE.0b013e3181f7b679. Epub 2010 Nov 3. PubMed PMID: 21048099.

Related Products
  • CAS No. :1113403-10-4
    Product Name:

    Dexibuprofen lysine

    Cat No: I011893 View details
  • CAS No. :663172-95-0 (HCl)
    Product Name:

    BN-82451 HCl

    Cat No: I004776 View details
  • CAS No. :132-69-4 (HCl)
    Product Name:

    Benzydamine Hydrochloride

    Cat No: I004157 View details
  • CAS No. :23779-99-9
    Product Name:

    Floctafenine

    Cat No: R055425 View details